Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPSP156
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
01
Overview
NPSP156 is a proprietary small molecule D-serine analog developed by NPS Pharmaceuticals. It acts as an endogenous ligand at the glycine binding site of the N-methyl-D-aspartate (NMDA) receptor, functioning as a co-agonist to modulate excitatory neurotransmission. The compound was nominated as a candidate for preclinical development in 2006 for the potential treatment of various neurological disorders. However, NPS Pharmaceuticals did not advance the drug into clinical development and instead sought to out-license the compound, resulting in its status as an inactive or discontinued preclinical asset.
- Other names
- D-serine analog
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on NPSP156.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NPSP156.